BioCryst Pharmaceuticals (BCRX) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 32.1% versus a gain of 13.9%. Over five years, INCY leads with a +72.0% price change compared with -45.2% for BCRX. Incyte is the larger company by market cap ($22.88 billion vs $2.16 billion), about 10.6 times the size, while BioCryst Pharmaceuticals is growing revenue faster (+94.1% vs +21.2%).
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (9.0x vs 12.9x for Incyte). BioCryst Pharmaceuticals converts more of its revenue into profit, with a net margin of 30.2% versus 25.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | INCY |
|---|---|---|
| Share price | $8.47 | $112.86 |
| Market cap | $2.16B | $22.88B |
| 1-day change | +2.11% | +0.10% |
| YTD return | +6.28% | +14.15% |
| 1-year return | +13.87% | +32.06% |
| 5-year return | -45.21% | +71.98% |
| P/E ratio (TTM) | — | 14.38 |
| Forward P/E | 9.01 | 12.90 |
| EPS (TTM) | $-1.40 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | $5.14B |
| Revenue growth (YoY) | +94.10% | +21.22% |
| Net income (latest FY) | $263.86M | $1.29B |
| Gross margin | 97.82% | 92.76% |
| Operating margin | 38.98% | 29.46% |
| Net margin | 30.16% | 25.03% |
| 52-week high | $11.22 | $132.60 |
| 52-week low | $6.00 | $82.82 |
| Distance from 52-week high | -24.55% | -14.89% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +144.89% | +14.42% |
| Average volume | 4.13M | 1.63M |
| Shares outstanding | 255.54M | 202.70M |
| Employees | 435 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 10.6 times larger than BioCryst Pharmaceuticals by market value ($22.88B vs $2.16B).
- INCY has outperformed BCRX by 18.2 percentage points over the past year.
- BioCryst Pharmaceuticals is more profitable, keeping 30.2 cents of every revenue dollar as net income versus 25.0 cents for Incyte.
- BioCryst Pharmaceuticals grew revenue faster in its latest fiscal year (+94.10% vs +21.22%).
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
BCRX vs INCY FAQ
Which is bigger, BioCryst Pharmaceuticals or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.88B compared with $2.16B for BioCryst Pharmaceuticals (BCRX).
Which stock has performed better over the past year, BCRX or INCY?
INCY returned +32.06% over the past 12 months, compared with +13.87% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Incyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioCryst Pharmaceuticals and Biotechnology: Commercial Physical & Biological Resarch for Incyte.